Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mogamulizumab - Kyowa Kirin

Next Previous
X
Search
Drug Profile

Mogamulizumab - Kyowa Kirin

Alternative Names: AMG 761; KW-0761; Mogamulizumab-kpkc; Poteligeo

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Amgen; Bristol-Myers Squibb; Kyowa Hakko; Kyowa Hakko Kirin; Kyowa Kirin; Memorial Sloan-Kettering Cancer Center; Ono Pharmaceutical
  • Class Antiasthmatics; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR4 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Sezary syndrome; Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma; Mycosis fungoides; Spinal cord disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult T-cell leukaemia-lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; Sezary syndrome
  • No development reported Non-small cell lung cancer
  • Discontinued Asthma; Hypersensitivity; Solid tumours; Spinal cord disorders

Most Recent Events

  • 07 Aug 2024 Kyowa Kirin enters into a distribution agreement with NewBridge Pharmaceuticals to commercialize mogamulizumab in Middle East and North Africa
  • 31 Jul 2024 Polish Ministry of Health approves reimbursement of mogamulizumab in Mycosis fungoides and Sézary syndrome
  • 30 Sep 2023 Preregistration for Mycosis fungoides in Singapore, Taiwan (IV) before September 2023 (Kyowa Kirin pipeline, February 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top